NasdaqGM - Nasdaq Real Time Price USD

Amarin Corporation plc (AMRN)

0.8700

-0.0086

(-0.98%)

As of 10:12 AM EDT. Market Open.

Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event

Citizen Petition Spotlights Risks for Patients on Drug Proven to Have No Benefit in Improving Cardiovascular Outcomes and Need for Urgent Regulatory Action to Protect PatientsDUBLIN, Ireland and BRIDGEWATER, N.J., April 24, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced its support for a petition filed with the U.S. Food and Drug Administration (FDA) requesting that the Commissioner focus on and take further action to address significant off-label prescribing of fe

GlobeNewswire 20 hours ago

AMRN
-0.98%
Amarin Announces Results of Annual General Meeting of Shareholders

- Shareholders Approve Share Repurchase Program of up to $50 Million -DUBLIN, Ireland and BRIDGEWATER, N.J., April 22, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced shareholder approval of all proposed resolutions specified at its 2024 Annual General Meeting (AGM). Importantly, shareholders approved each of the two proposals required for the Company to proceed with its previously announced intent to pursue a share repurchase program of up to $50 million. This perm

GlobeNewswire 3 days ago

AMRN
-0.98%
Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024

DUBLIN, Ireland and BRIDGEWATER, N.J., April 15, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Patrick Holt, President & CEO, and members of Amarin’s senior management team to discuss its first quarter 2024 results followed by Q&A on Wednesday, May 1st, 2024, at 8:00 a.m. ET. The conference call with management will follow the release of the Company’s first quarter 2024 financial results in the pre-market hours. To enhance

GlobeNewswire 10 days ago

AMRN
-0.98%
Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24

Data Further Advance Understanding of VASCEPA®/VAZKEPA® Potential Mechanism of ActionDUBLIN, Ireland and BRIDGEWATER, N.J., April 08, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today highlighted three data presentations at ACC.24 showcasing the mechanistic activity of Eicosapentaenoic acid (EPA), including the potential effects of EPA on endothelial cell dysfunction and on oxidation of samples enriched with Lp(a). ”The data presented at ACC.24 provide new evidence surrounding

GlobeNewswire 17 days ago

AMRN
-0.98%
New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups

HLS Therapeutics Inc. (HLS or the Company) (TSX: HLS), a pharmaceutical company focusing on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, today highlighted two data presentations at the 73rd Annual Scientific Sessions of the American College of Cardiology (ACC.24) describing the effects of VASCEPA (icosapent ethyl) on reducing Major Adverse Cardiovascular Events (MACE) in patients with baseline high or low Lipoprotein(a) [Lp(a)] levels, as well as r

CNW Group 17 days ago

HLTRF

AMRN
-0.98%
New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups

-- Findings Presented on VASCEPA/VAZKEPA Utility in REDUCE-IT Patient Subgroups by Baseline High/Low Lp(a), LDL-C Levels -- -- Lp(a) Results Published Simultaneously in the Journal of the American College of Cardiology (JACC) – DUBLIN, Ireland and BRIDGEWATER, N.J., April 06, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today highlighted two data presentations at ACC.24 describing the effects of VASCEPA®/VAZKEPA® (icosapent ethyl) on reducing MACE (Major Adverse Cardiovascular E

GlobeNewswire 18 days ago

AMRN
-0.98%
Amarin (AMRN) Up 7% on Intellectual Property Wins in Europe

Amarin (AMRN) secures a new patent for Vazkepa in Europe, which extends its exclusivity for eight more years. It achieves success in defending another patent on the drug against third parties.

Zacks 20 days ago

AMRN
-0.98%
LGNZZ

ANIP
Why Amarin Stock Was Rocketing Higher on Wednesday

There was unambigously good news about the company's single commercialized medication.

Motley Fool 21 days ago

AMRN
-0.98%
^GSPC
Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe

Company’s IP Protection for VAZKEPA® in Europe Now Extended Into 2039DUBLIN, Ireland and BRIDGEWATER, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that the Company received a Decision to Grant from the European Patent Office (EPO) for a new patent covering VAZKEPA® (icosapent ethyl) that will extend VAZKEPA exclusivity eight additional years into 2039. In addition, the Company recently achieved success defending a separate European VAZKEPA patent

GlobeNewswire 22 days ago

AMRN
-0.98%
Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo

-- Subgroup Analyses from REDUCE-IT® and Mechanistic Data on Icosapent Ethyl(IPE)/Eicosapentaenoic Acid (EPA) Featured at the Meeting -- DUBLIN, Ireland and BRIDGEWATER, N.J., March 25, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that additional patient subgroup analyses from the landmark REDUCE-IT outcomes trial and mechanistic data on icosapent ethyl (IPE)/eicosapentaenoic acid (EPA) will be presented at the American College of Cardiology’s Annual Scientific S

GlobeNewswire last month

AMRN
-0.98%
Amarin Full Year 2023 Earnings: Beats Expectations

Amarin ( NASDAQ:AMRN ) Full Year 2023 Results Key Financial Results Revenue: US$306.9m (down 17% from FY 2022). Net...

Simply Wall St. last month

AMRN
-0.98%
Earnings Update: Amarin Corporation plc (NASDAQ:AMRN) Just Reported And Analysts Are Trimming Their Forecasts

It's been a sad week for Amarin Corporation plc ( NASDAQ:AMRN ), who've watched their investment drop 11% to US$1.06 in...

Simply Wall St. last month

AMRN
-0.98%
Amarin's (AMRN) Q4 Earnings and Revenues Surpass Estimates

Amarin's (AMRN) fourth-quarter 2023 earnings and revenues beat estimates. Vascepa's sales in the United States decline year over year.

Zacks last month

AMRN
-0.98%
PBYI

ADMA
Amarin Corporation plc (NASDAQ:AMRN) Q4 2023 Earnings Call Transcript

Amarin Corporation plc (NASDAQ:AMRN) Q4 2023 Earnings Call Transcript February 29, 2024 Amarin Corporation plc beats earnings expectations. Reported EPS is $-0.01, expectations were $-0.04. AMRN isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Welcome to Amarin Corporation’s Conference Call […]

Insider Monkey last month

AMRN
-0.98%
Amarin Plc (AMRN) Q4 2023 Earnings Call Transcript

AMRN earnings call for the period ending December 31, 2023.

Motley Fool last month

AMRN
-0.98%
Amarin Corp PLC (AMRN) Faces Revenue Decline Amidst Generic Competition

Full-Year 2023 Earnings Reveal Challenges and Strategic Focus on Cash Flow

GuruFocus.com last month

AMRN
-0.98%
Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

-- Company Delivers Total Revenues of $75 Million in the Fourth Quarter and $306 Million for the Full-Year 2023 ---- Reaffirms Year-End 2023 Cash Position of $321 Million and Full-Year Positive Cash Flow of $10 Million -- -- Company Reports Fourth Quarter 2023 Total Operating Expense of $50 Million ---- Initiated Shareholder Approval Process to Execute a Share Repurchase Program of up to $50 Million by the End of the Second Quarter 2024 ---- Company to Host Conference Call Today at 8:00 a.m. EDT

GlobeNewswire last month

AMRN
-0.98%
Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024

DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Patrick Holt, President & CEO, and members of Amarin’s senior management team to discuss its fourth quarter and year end 2023 results on Thursday, February 29th, 2024, at 8:00 a.m. ET. The call will include brief remarks on 2023 highlights followed by Q&A. The conference call with management will follow the release of the Company’s

GlobeNewswire 2 months ago

AMRN
-0.98%
5 Biotech Stocks Likely to Outpace Q4 Earnings Estimates

Let us look at some drug/biotech stocks, MRNA, BMRN, AMRN, NTLA and BEAM, which are poised to beat on fourth-quarter earnings.

Zacks 2 months ago

NTLA

MRNA

BMRN
Amarin Chairman & CEO Issue Letter to Shareholders

DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 22, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that the Company’s Chairman of the Board, Odysseas Kostas, M.D., and President & CEO, Patrick Holt, issued the following letter to Amarin shareholders: Dear Fellow Amarin Shareholders, 2023 was an important year for Amarin, marked by necessary transition and change. With a new board focused on shareholders, we undertook significant actions to strengthen the Company. We re

GlobeNewswire 3 months ago

AMRN
-0.98%

Performance Overview

Return	AMRN	MSCI WORLD
YTD	0.00%	+3.59%
1-Year	-34.09%	+16.13%
3-Year	-83.04%	+11.43%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Amarin Corporation plc (AMRN)

Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event

Amarin Announces Results of Annual General Meeting of Shareholders

Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024

Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24

New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups

New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups

Amarin (AMRN) Up 7% on Intellectual Property Wins in Europe

Why Amarin Stock Was Rocketing Higher on Wednesday

Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe

Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo

Amarin Full Year 2023 Earnings: Beats Expectations

Earnings Update: Amarin Corporation plc (NASDAQ:AMRN) Just Reported And Analysts Are Trimming Their Forecasts

Amarin's (AMRN) Q4 Earnings and Revenues Surpass Estimates

Amarin Corporation plc (NASDAQ:AMRN) Q4 2023 Earnings Call Transcript

Amarin Plc (AMRN) Q4 2023 Earnings Call Transcript

Amarin Corp PLC (AMRN) Faces Revenue Decline Amidst Generic Competition

Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024

5 Biotech Stocks Likely to Outpace Q4 Earnings Estimates

Amarin Chairman & CEO Issue Letter to Shareholders

Performance Overview